Orange County Business Journal reported that Irvine firm SpyGlass Pharma, led by Patrick Mooney, has transitioned its corporate footprint into the city following a strategic relocation completed earlier this year.

The enterprise, which was originally founded in 2019 by Malik Kahook and Glenn Sussman, focuses on medical technology development. Specifically, the firm is developing a glaucoma implant lasting up to three years. To accommodate its ongoing growth and operational requirements, the company officially moved its operations from Aliso Viejo to its new Irvine headquarters in August. This headquarters space holds capacity for 150 employees, providing room for the workforce as research and development continue.

In terms of financial capitalization, the company achieved a major milestone by generating substantial funds through public markets. The firm grossed $172.5M from a February initial public offering priced at $16 per share. This capital injection supports the ongoing efforts of the firm as it works toward its projected product milestones.

Looking ahead at the long-term corporate timeline, the company is officially targeting a commercial launch in year 2029. This schedule guides the development of the glaucoma implant lasting up to three years, moving from the foundational work established at its 2019 inception by Malik Kahook and Glenn Sussman toward broader market availability.

Patrick Mooney leads Irvine firm SpyGlass Pharma through these operational and developmental phases. Addressing the broader corporate vision following the move of operations from Aliso Viejo to the Irvine headquarters in August—a facility where the headquarters space holds capacity for 150 employees—Patrick Mooney told Orange County Business Journal, “We’re building this company for decades, not just the phase of flight we’re in.”

The progression of SpyGlass Pharma reflects the combination of initial establishment by Malik Kahook and Glenn Sussman in 2019, the financial backing secured from the February initial public offering priced at $16 per share which grossed $172.5M, and the current operational setup under the leadership of Patrick Mooney as the company works toward the targeted commercial launch in year 2029.